Determining vancomycin clearance in an overweight and obese population
Authors:
- 1 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 68 (7) , 599-603
Abstract
Two methods of calculating vancomycin clearance were compared to determine the best body weight measure to use when dosing vancomycin for overweight and obese patients. Hospitalized veterans weighing more than 120% of their ideal body weight (IBW) with serum vancomycin concentrations (SVCs) drawn between January 1, 2003, and June 30, 2005, were eligible for study inclusion. Exclusion criteria included weight of more than 300% the IBW, unstable renal function, dialysis, uncertain vancomycin dosing or sampling times, and distribution-phase sampling. Data from January 1 through December 31, 2003 (phase 1) determined the best-fit weight for vancomycin clearance for the Leonard and Boro method. The bias and precision of the modified Leonard and Boro method using the best-fit weight for vancomycin clearance were then compared with those of the Rushing and Ambrose method for predicting SVCs from January 1, 2004, through June 30, 2005 (phase 2). Forty-eight patients were included in phase 1, with 67 SVCs for analysis. During phase 1, adjusted body weight (ABW), using the Leonard and Boro method, was superior in predicting vancomycin clearance and the resultant SVCs. A total of 96 patients were included in phase 2 of the study, with 160 SVCs for analysis. The modified Leonard and Boro method was significantly more precise than the Rushing and Ambrose method in predicting vancomycin clearance. Use of ABW proved to be superior compared with total body weight when estimating vancomycin clearance in overweight and obese patients. While there was no difference in bias between methods, the modified Leonard and Boro method was significantly more precise than the Rushing and Ambrose method in predicting SVCs when dosing vancomycin for obese patients.Keywords
This publication has 17 references indexed in Scilit:
- Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistantStaphylococcus aureusAmerican Journal of Health-System Pharmacy, 2010
- Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and TelavancinInfectious Disease Clinics of North America, 2009
- Therapeutic Monitoring of Vancomycin in AdultsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsAmerican Journal of Health-System Pharmacy, 2009
- Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapyAmerican Journal of Health-System Pharmacy, 2005
- ASHP national survey of pharmacy practice in hospital settings: Monitoring and patient education--2003American Journal of Health-System Pharmacy, 2004
- Clinical Application and Evaluation of Vancomycin Dosing in AdultsJournal of Pharmacy Technology, 2001
- Vancomycin dosing in morbidly obese patientsEuropean Journal of Clinical Pharmacology, 1998
- Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting techniqueAntimicrobial Agents and Chemotherapy, 1993
- Vancomycin pharmacokinetics in normal and morbidly obese subjectsAntimicrobial Agents and Chemotherapy, 1982